MedTrace Logo

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

NCT05551741 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-24

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled first-in-human, Phase 1, safety, tolerability, pharmacokinetic (PK) and preliminary exploratory activity study of escalating multiple intravenous (IV) doses of IBC-Ab002 in persons with early Alzheimer's disease. The study will have both Single- and Multiple-Ascending Dose components.

Conditions

Interventions

BIOLOGICAL

IBC-Ab002

An anti-PD-L1 monoclonal antibody

OTHER

Placebo

Normal Saline

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Alzheimer's Association

    collaborator OTHER

  • Immunobrain Checkpoint

    lead INDUSTRY

Principal Investigators

  • Tommaso Croese, MD · Immunobrain Checkpoint

  • Catherine Mummery, MD · Dementia Research Centre, UCL, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2025-12-16
Completion
2025-12-16

Countries

  • Israel
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05551741 on ClinicalTrials.gov